secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2023-11-03T23:59:59+00:00
Accession:  0001558370-23-017593
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio reports XTX202 Phase 1/2 data: 50% disease control at ≥2.8 mg/kg, no vascular leak syndrome
--------------------------------------------------------------------------------

- 62 patients dosed; 42 evaluable for activity: 31% disease control rate (13 SD ≥9 wks) across all doses, 50% at ≥2.8 mg/kg (3/6).
- No signs/symptoms of vascular leak syndrome; TRAEs primarily Grade 1-2; no discontinuations due to TRAE.
- Two patients on treatment >1 year (MSS CRC and RCC); dose-dependent PK with ~15% activated drug in tumor vs <1% in plasma.
- Plan to evaluate XTX202 at 4.0 mg/kg in Phase 2 for melanoma and RCC; initial data expected Q2 2024.
- Milestones subject to additional capital: XTX101 combo Phase 2 start Q3 2024, XTX301 data H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837023017593/0001558370-23-017593-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837023017593/xlo-20231103x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-017593

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer